Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IdeaSphere markets Weil

This article was originally published in The Tan Sheet

Executive Summary

IdeaSphere will "assume exclusive, worldwide licensing rights" to Weil Nutritional Supplements, the New York-based firm announced Jan. 17. The product line, which was launched in March by author Andrew Weil, MD, currently is sold through Weil's website and in specialty health stores such as Whole Foods, GNC and Vitamin Shoppe. IdeaSphere will take over retail and direct marketing of the supplement line including online sales, the company states. IdeaSphere purchased Twinlab in 2003 and most recently completed the acquisition of Metabolife's non-ephedra brands including Metabolife Ultra in November (1"The Tan Sheet" Sept. 1, 2003, p. 3 and 2"The Tan Sheet" Nov. 14, 2005, In Brief)...

You may also be interested in...



Twinlab Finds Potential Buyer In IdeaSphere: End Of Blechman Era?

The proposed acquisition of Twinlab by nutritional products seller IdeaSphere would mark the end of the Blechman family ownership of the company, in place since the company's founding 35 years ago

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel